Glaxo Smith Kline results, Fiscal year 2024
Net profit, assets, equity and cash flow for Fiscal year 2024, against the same period a year earlier, from the published financial statements.
Net profit174 millionEGP · +187.8% vs the same period a year earlier
Total assets3.65 billionEGP · +2.7% vs the same period a year earlier
Shareholders' equity2 billionEGP · +1.5% vs the same period a year earlier
Operating cash flow-404 millionEGP · −233.7% vs the same period a year earlier
In short
- Glaxo Smith Kline's net profit for Fiscal year 2024 was about 174 million EGP, up +187.8% from 60.46 million EGP in Fiscal year 2023.
- Total assets at the end of Fiscal year 2024 were about 3.65 billion EGP, and shareholders' equity about 2 billion EGP.
- Operating cash flow for Fiscal year 2024 was negative at 404 million EGP.
Key lines against the same period a year earlier
This periodFiscal year 2023Change
Net profit174 million60.46 million+187.8%
Gross profit1.14 billion877 million+30.4%
Total assets3.65 billion3.56 billion+2.7%
Total liabilities1.66 billion1.59 billion+4.0%
Shareholders' equity2 billion1.97 billion+1.5%
Total liabilities and equity3.65 billion3.56 billion+2.7%
Operating cash flow-404 million302 million−233.7%
Investing cash flow-226 million85.5 million−364.4%
Financing cash flow-124 million-144 million+14.3%
Net change in cash-754 million243 million−409.6%
Figures in EGP from the published statement summaries (consolidated where the company publishes consolidated statements), after normalising reporting units across periods. The exact figure is in the attached report, which may be the standalone version.
Glaxo Smith Kline's Q3 2026 results, the day they are published
One email on the day, no account, and a one-click stop in the email itself.
By subscribing you agree to receive these alerts only. Privacy policy